Cabergoline Tablets
Overview of Cabergoline Tablets
Dosage Strength
0.5 mgGeneral Information
Cabergoline is a synthetic ergoline-derived dopamine agonist used to treat hyperprolactinemic diseases that are either idiopathic or caused by pituitary adenomas. Bromocriptine was the only FDA-approved medication for the treatment of hyperprolactinemias until the availability of cabergoline in 1996. According to the findings of comparative studies, cabergoline is more effective than bromocriptine in decreasing prolactin secretion and has a better tolerability profile. Furthermore, cabergoline’s unique dosing technique is a possible advantage of the medicine. Cabergoline has a long half-life and is provided once to twice weekly for hyperprolactinemia, but bromocriptine takes numerous daily doses to be effective. Despite indications that cabergoline is effective in the treatment of restless legs syndrome, it is rarely utilized in clinical practice due to the danger of cardiac valvulopathy and the availability of safer alternatives. 1223
References
1.Webster J, Piscitelli G, Polli A, et al. A comparison of cabergoline and bromocriptine in the treatment of hyperprolactinemic amenorrhea. N Engl J Med 1994;331:904-909.
2.Dostinex (cabergoline) package insert. Kalamazoo, MI: Pharmacia and Upjohn Company; 2019 Dec.
3.Aurora RN, Kristo DA, Bista SR, et al. The treatment of restless legs syndrome and periodic limb movement disorder in adults-an update for 2012: practice parameters with an evidence-based systematic review and meta-analyses: an American Academy
4.Iller BM, Molitch ME, Vance ML, et al. Treatment of prolactin-secreting macroadenomas with the once-weekly dopamine agonist cabergoline. J Clin Endocrin Metabol 1996;81:2338-2343.
5.Dostinex (cabergoline) package insert. Kalamazoo, MI: Pharmacia and Upjohn Company; 2019 Dec
Legal Disclaimer: All information presented in this website is intended for informational purposes only and not for the purpose of rendering medical advice.